Sofia Dembski

Dr. Sofia Dembski currently serves as the Head of the "Theranostics" research group at the Fraunhofer Institute for Silicate Research ISC, where she leads pioneering efforts in the development of multifunctional inorganic micro- and nanoparticles for biomedical applications. Her role involves strategic project management, interdisciplinary collaboration, and the translation of innovative nanotechnologies into clinical solutions. Under her leadership, the team focuses on designing and synthesizing targeted theranostic agents that combine diagnostic and therapeutic functionalities, particularly for oncology and musculoskeletal diseases. These advanced nanoparticles are engineered to improve drug delivery efficiency, enable real-time imaging, and minimize side effects, thereby opening new avenues for personalized medicine.

Sofia’s expertise spans wet-chemical synthesis, surface modification, and characterization of inorganic nanomaterials, leveraging her extensive background in chemistry and physical sciences. Her work is highly interdisciplinary, integrating principles from chemistry, materials science, and medicine to develop next-generation theranostic platforms. She actively collaborates with the Translational Center Würzburg, facilitating the translation of laboratory innovations into clinical applications through translational research projects. Sofia’s leadership in this field underscores her commitment to advancing nanomedicine and regenerative therapies, with a focus on innovative nanoparticle-based solutions that address unmet medical needs.

Her skills in project management, team coordination, and scientific communication—such as delivering engaging presentations and managing complex research initiatives—are instrumental in driving the success of her team. Sofia’s contributions continue to position the Fraunhofer ISC as a leader in nanotechnology-driven theranostics, fostering breakthroughs that could revolutionize diagnostics and targeted therapy in the near future.